532 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék. 2023;69(8):525-532 / www.casopisvnitrnilekarstvi.cz DOPORUČENÝ POSTUP Doporučený postup diagnostiky a léčby chronické hepatitidy D. Datum vydání doporučení: 2023 kandidátním lékem pro časově omezenou léčbu CHD. Jeho účinnost a bezpečnostní spektrum je nutné prověřit v dalších klinických studiích (3). Tento doporučený postup byl schválen výbory SIL ČLS JEP a ČHS ČLS JEP v roce 2023. LITERATURA 1. Husa P, et al. Diagnosis and therapy of hepatitis B virus infection: Czech national guidelines. Date of release: September 2017. Klin. Mikrobiol. Infekcni Lek. 2017;23:148-164. 2. Husa P, et al. Diagnosis and therapy of hepatitis B virus infection – Czech national guidelines. Gastroenterol. Hepatol. 2017;71:419-437. 3. Brunetto MR, et al. EASL Clinical Practice Guidelines on hepatitis delta virus. J. Hepatol 2023:79,433-460. 4. Walker PJ, et al. Changes to virus taxonomy and to the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2021). Arch. Virol. 2021;166:2633-2648. 5. Papatheodoridi M, Papatheodoridis GV. Is hepatitis delta underestimated? Liver Int. 2021;41:38-44. 6. Miao Z, et al. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J. Infect., DiS. 2020;221:1677-1687. 7. Chen H‑Y, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta‑analysis. Gut. 2019;68:512-521. 8. Stockdale AJ, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta‑analysis. J. Hepatol. 2020;73:523-532. 9. Lampertico P, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 2017;67:370-398. 10. Sarin SK, et al. Asian‑Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol. Int. 2016;10:1-98. 11. Terrault NA, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018; 67:1560. 12. Palom A, et al. Implementation of anti‑HDV reflex testing among HBsAg‑positive individuals increases testing for hepatitis D. JHEP Rep. 2022;4:100547. 13. Buti M, Esteban R, Jardí R, et al. Serological diagnosis of acute delta hepatitis. J. Med. Virol. 1986;18:81-85. 14. Romeo R, et al. High Serum Levels of HDV RNA Are Predictors of Cirrhosis and Liver Cancer in Patients with Chronic Hepatitis Delta. PLOS ONE. 2014;9:e92062. 15. Ricco G, et al. Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection. J. Viral Hepat. 2018;25:911-919. 16. Palom A, et al. One‑quarter of chronic hepatitis D patients reach HDV‑RNA decline or undetectability during the natural course of the disease. Aliment. Pharmacol. Ther. 2021;54:462-469. 17. Caredda F, et al. Incidence of Hepatitis Delta Virus Infection in Acute HBsAg‑Negative Hepatitis. J. Infect., DiS. 1989;159:977-979. 18. Kamal H, et al. Long‑Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver‑Related Outcomes. Hepatology. 2020;72:1177. 19. Berzigotti A, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011;54:555-561. 20. El–Serag HB, Hampel H, Javadi F. The Association Between Diabetes and Hepatocellular Carcinoma: A Systematic Review of Epidemiologic Evidence. Clin. Gastroenterol. Hepatol. 2006;4:369-380. 21. Zachou K, et al. Quantitative HBsAg and HDV‑RNA levels in chronic delta hepatitis. Liver Int. 2010;30:430-437. 22. Asselah T, et al. Improving the Accuracy of Non‑Invasive Test for prediction of cirrhosis in CHD: insight from 230 patients from D‑liver study. J Hepatol. 2021;75:S637-S638 23. Diaz G, et al. Molecular Signature and Mechanisms of Hepatitis D Virus–Associated Hepatocellular Carcinoma. Mol. Cancer. Res. 2018;16:1406-1419. 24. Caviglia GP, et al. The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. J. Adv. Res. 2021;33:183-187. 25. Roulot D, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. J. Hepatol. 2020;73:1046-1062. 26. Romeo R, et al. A 28-Year Study of the Course of Hepatitis Δ Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma. Gastroenterology. 2009;136:1629-1638. 27. Osiowy C, et al. Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada. JHEP Rep. 2022;4:100461. 28. Tzartzeva K, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta‑analysis. Gastroenterology. 2018;154:1706-1718.e1. 29. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018;69:182-236. 30. Ricco G, et al. Highly dynamic changes of regional HBV epidemiology over two decades. Dig. Liver, DiS. 2023;55:519-526. 31. Abdrakhman A, Ashimkhanova A, Almawi WY. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta‑analysis. Antiviral Res. 2021;185:104995. 32. Wedemeyer H, et al. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D. N. Engl. J. Med. 2023;389:22-32. 33. Zhang Z, et al. Hepatitis D virus‑induced interferon response and administered interferons control cell division‑mediated virus spread. J. Hepatol. 2022;77:957-966. 34. Bogomolov P, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J. Hepatol. 2016;65:490-498. 35. Wedemeyer H, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel‑group, open‑label, phase 2 trial. Lancet Infect., DiS. 2023;23:117-129. 36. Wedemeyer H, et al. GS-13-Final results of a multicenter, open‑label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG‑interferon Alpha 2a in patients with chronic HBV/HDV co‑infection. J. Hepatol. 2019;70:e81. 37. Stoll F, et al. Metabolic Effect of Blocking Sodium‑Taurocholate Co‑Transporting Polypeptide in Hypercholesterolemic Humans with a Twelve‑Week Course of Bulevirtide–An Exploratory Phase I Clinical Trial. Int. J. Mol. Sci. 2022;23:15924. 38. Schaper M, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J. Hepatol. 2010;52:658-664. 39. Samuel D, et al. Long‑term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology.1995;21:333-339. 40. Akarsu M, et al. Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. Turk. J. Gastroenterol. 2021;2:712-719.
RkJQdWJsaXNoZXIy NDA4Mjc=